Q-omics provides the consensus-scored CNPPD1 profile across patient tissues and cancer cell-line models. CNPPD1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CNPPD1 is differentially expressed in 14, with the highest sampling consensus in LIHC. Additionally, CNPPD1 RNA expression shows 18,728 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LIHC, and ACC as cancer lineages where CNPPD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNPPD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNPPD1 survival associations across molecular data types. CNPPD1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNPPD1 RNA expression–survival associations across cancer types. High CNPPD1 expression shows unfavorable associations in LIHC and OV, but favorable associations in KIRC, KIRP, UVM and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CNPPD1 RNA expression.
This table summarizes CNPPD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CNPPD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNPPD1 shows lower tumor expression in THCA, KICH and COAD and higher tumor expression in LIHC, BRCA and STAD. The LIHC box plot shows higher CNPPD1 RNA expression in tumor versus normal tissue (log2 FC = +1.031, t-test p < 0.001).
This table shows molecular features associated with CNPPD1 in patient tissues and cancer cell lines. In patient samples, CNPPD1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CNPPD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
